FindTrial
Sign In

Inflammatory phenotypes and clinical features of immune-associated interstitial pneumonia after tumor immunotherapy: a multicenter, retrospective study

Inflammatory phenotypes and clinical features of immune-associated interstitial pneumonia after tumor immunotherapy: a multicenter, retrospective study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065859
Enrollment
Unknown
Registered
2022-11-17
Start date
2022-11-17
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

checkpoint inhibitor-related pneumonitis

Interventions

Case series:Nil

Sponsors

Nanfang Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years (inclusive), male or female; 2. ECOG score: 0 ~ 4; 3. Tumor was confirmed by pathological diagnosis; 4. Received tumor-related immunotherapy; 5. Immune-associated interstitial pneumonia occurs during or after immunotherapy; 6. Good compliance of subjects.

Exclusion criteria

Exclusion criteria: 1. Patients who are using immunotherapy drugs in clinical trials; 2. Immune-associated pneumonia complicated by pulmonary inflammation caused by bacteria, viruses, Mycobacterium tuberculosis and other infections; 3. Immune-associated pneumonia combined with radiation pneumonitis; 4. Immune-associated pneumonia combined with obstructive pneumonia caused by tumor progression.

Design outcomes

Primary

MeasureTime frame
Classification of cells;Imaging;—

Countries

China

Contacts

Public ContactDong Hangming

Nanfang Hospital of Southern Medical University

huidhm@126.com+86 18688426705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026